Alphatec (NASDAQ:ATEC) Major Shareholder Jennifer Pritzker Sells 250,000 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) major shareholder Jennifer Pritzker sold 250,000 shares of Alphatec stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $20.62, for a total value of $5,155,000.00. Following the completion of the transaction, the insider owned 10,895,045 shares in the company, valued at $224,655,827.90. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Alphatec Stock Performance

ATEC stock opened at $22.59 on Thursday. Alphatec Holdings, Inc. has a one year low of $8.69 and a one year high of $22.66. The firm has a market cap of $3.36 billion, a price-to-earnings ratio of -19.99 and a beta of 1.17. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88. The firm has a 50-day simple moving average of $16.88 and a two-hundred day simple moving average of $14.38.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. During the same quarter last year, the firm earned ($0.28) EPS. The company’s revenue was up 30.4% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on ATEC. Morgan Stanley upped their target price on Alphatec from $16.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. JPMorgan Chase & Co. started coverage on shares of Alphatec in a research note on Friday, October 24th. They issued an “overweight” rating and a $19.00 target price for the company. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a report on Monday. Finally, Wells Fargo & Company boosted their price objective on shares of Alphatec from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $22.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd acquired a new stake in Alphatec during the 3rd quarter worth about $34,000. Osterweis Capital Management Inc. acquired a new position in shares of Alphatec in the 2nd quarter valued at about $37,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alphatec in the third quarter worth about $73,000. Nisa Investment Advisors LLC boosted its stake in shares of Alphatec by 22.4% in the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after buying an additional 1,045 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new stake in Alphatec during the third quarter worth about $120,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.